Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > All Ingredients News

Cure not kill: Dynamite ingredient can improve cancer treatment says study

27-Aug-2015 - Nitroglycerin could make cancer drugs more effective say researchers trying to use the dynamite ingredient to help destroy tumours.

To supply the Dane: Novo expects First API batch in 2020

27-Aug-2015 - Novo Nordisk has confirmed it will build an API plant in the US, telling this publication a desire to have manufacturing capacity in the key market for its oral diabetes candidate, semaglutide, drove the decision.

DSM says plans to cut 1,100 jobs prompted by recent pharma moves not shareholder pressure

25-Aug-2015 - Royal DSM will make up to 1100 staff redundant by the end of 2017 to cut costs following the formation of its Sinochem JV and pharma products deal with Patheon.

News in brief

AmbioPharma expands US manufacturing site and starts work on global HQ

24-Aug-2015 - Peptide maker AmbioPharma will invest $18.8m to expand its manufacturing operations in South Carolina in a move that it claims will create 100 jobs.

Xellia moves US HQ to North Carolina

20-Aug-2015 - Anti-infectives firm Xellia has moved its North American HQ to the lyophilisation plant in Raleigh, North Carolina that it bought from Fresenius Kabi last July .

Excipient manufacturers raise concerns over stability testing

13-Aug-2015 - Manufacturers of excipients are being sent inappropriate requests for stability data by some regulators and pharma companies, threatening to disrupt the supply chain, IPEC claims.

Laser synthesis technique could provide better APIs

12-Aug-2015 - Scientists in Japan have developed a technique for making crystal forms of active pharmaceutical ingredients (APIs) that until now have been hard to synthesise.

Next-gen APIs will exploit ‘bugs’ in human gut

11-Aug-2015 - Small molecules from our gut microbes are providing the APIs for future drugs. 

Merck & Co is second licensing deal for biocatalyst maker after GSK

05-Aug-2015 - Codexis has licensed its biocatalysis tech to Merck & Co. for up to $26m one year after signing a similar deal with GSK.

AMRI acquisitions driving up contract revenue in Q2

05-Aug-2015 - With contract revenue growth of nearly 40%, CDMO (contract development and manufacturing organization) AMRI is seeing its acquisitions of OsoBio , two Aptuit facilities and a UK aseptic facility pay off.

Currency issues impacting API manufacturers’ bottom lines

04-Aug-2015 - API makers are looking for ways to slash costs and improve efficiencies to counter the impact currency fluctuations and other market challenges, earnings results from Lonza and BASF show.

'Rough notes' and backdated signatures land Indian API maker US FDA warning

29-Jul-2015 - Issues with batch production records at an Indian facility have landed API maker Mahendra Chemicals with a US FDA warning letter.

Less than a year to risk assess excipients: IPEC Europe develops 'how to' guide

27-Jul-2015 - IPEC Europe has reminded drugmakers they have less than a year to risk assess all excipients used in their products under recently introduced EU rules.

Ethiopia: GMP compliant local drug and API sector would yield health and economic benefits

22-Jul-2015 - Ethiopia will start making its own APIs in 2020 according to the Government which says local manufacture will improve access to medicines, curb sale of counterfeits and promote innovation.

Lonza: global hedge helped offset currency exposure but Visp still a risk

22-Jul-2015 - Lonza has reported higher revenues and profits for H1 2015, but warned that the strength of the Swiss franc means its Visp facility is still finding it hard to compete.

Johnson Matthey’s API business flat in Q1 on timing of opiate API orders

22-Jul-2015 - Johnson Matthey saw lower demand for opiate APIs in the three months to the end of June, which offsett more solid performance by its attention deficit hyperactivity disorder (ADHD) drug actives.

IPEC calls on FDA to establish new review process for novel excipients

22-Jul-2015 - As part of a push to bring more novel excipients to market, IPEC-Americas is calling on the FDA to create a new regulatory review process that could relieve some of the uncertainty around the use of new excipients.

Green GMP criteria would help responsible API firms compete with polluters says DSM Sinochem

20-Jul-2015 - API firms that invest in waste management find it hard to compete with those that pollute according to DSM Sinochem, which wants environmental criteria included in GMP standards for environmental and business reasons.

Gadea's steroid intermediates biz means AMRI not reliant on Asian suppliers say execs

20-Jul-2015 - AMRI has bought Spanish contractor Gadea Pharmaceutical Group for $174m (€160m) to add muscle to its steroid API business and sign up more customers outside the US.

Nordea mulling holdings in drugmakers that source APIs from water polluters

16-Jul-2015 - Drugmakers risk losing financial backing if they source APIs from Indian suppliers that pollute according to Nordea Asset Management's head of responsible investments, Sasja Beslik.

Sandoz closing Mumbai API plant but says it remains committed to India

15-Jul-2015 - Sandoz will shutter an Indian API facility in 2016 as part of a manufacturing refocus in the region.

Environmental group welcomes DSM-Sinochem and GSK efforts to halt spread of antibiotic resistance

13-Jul-2015 - Antibiotic API makers have an obligation to ensure their activities do not spread resistance says a group that welcomed DSM-Sinochem’s commitment to environmentally-friendly production.

Lupin enters Russian market through Biocom deal

09-Jul-2015 - Lupin is set to acquire Russian generics maker Biocom, adding a GMP compliant facility and gaining access to the local market.

GSK back in China via new API manufacturing agreement with Desano

06-Jul-2015 - GSK’s HIV unit ViiV Healthcare and China-based Desano Pharmaceuticals have forged an agreement whereby Desano will manufacture the API of GSK’s HIV drug Tivicay (dolutegravir) in China.

GMP assessments should consider environmental impact say campaigners

06-Jul-2015 - A group calling for GMP assessments to consider the environmental impact of API production says pollution generated by suppliers in China is furthering the spread of resistant superbugs.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...